STOCK TITAN

Aclarion Inc - ACON STOCK NEWS

Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.

Aclarion Inc (ACON) delivers innovative diagnostic solutions for chronic low back pain through its Nociscan SaaS platform, combining MRS technology with AI-driven biomarker analysis. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical advancements, financial milestones, and strategic initiatives.

Access timely press releases covering FDA communications, peer-reviewed study results, and partnership announcements with leading medical institutions. Our curated collection includes earnings reports, technology updates, and market expansion developments critical for evaluating ACON's position in medical imaging innovation.

Bookmark this page for streamlined access to verified information about Nociscan's clinical adoption, intellectual property developments, and evidence-based research outcomes. Stay informed about ACON's progress in transforming spine diagnostics through objective, noninvasive solutions supported by proprietary signal processing algorithms.

Rhea-AI Summary
Aclarion, a healthcare technology company, has announced that Dr. Roger Hartl, a renowned neurosurgeon, will advise the company as a key opinion leader (KOL) nationally. Aclarion's Nociscan solution helps physicians identify the location of chronic low back pain noninvasively. Dr. Hartl will have access to an MRI center authorized to perform Nociscans in New York City, adding to the existing site in Denver. Aclarion plans to report on Nociscan volumes before the end of the year and include this metric in quarterly reporting from 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
none
-
Rhea-AI Summary
Aclarion, a healthcare technology company, announced that its Nociscan platform will be presented at the NIH HEAL Initiative BACPAC Research Program. Nociscan is a decision support tool that helps physicians identify the location of chronic low back pain. It is being utilized in two leading low back pain trials within the HEAL Initiative. The NIH HEAL Initiative aims to address the opioid crisis by funding research on chronic low back pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.87%
Tags
none
-
Rhea-AI Summary
Porter Hospital in Denver has become the first facility to offer Nociscan technology for chronic low back pain patients. The technology measures biomarkers to pinpoint the source of pain and has been shown to improve patient outcomes and reduce costs. Aclarion, the healthcare technology company behind Nociscan, is expanding its footprint in Colorado with AdventHealth Porter. The addition of Nociscan to the hospital's diagnostic evaluation is expected to improve treatment strategies and provide personalized biomarker data to physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.86%
Tags
none
Rhea-AI Summary
Aclarion's Nociscan cost-effectiveness study showcased at medical decision making meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.56%
Tags
none
-
Rhea-AI Summary
Aclarion and ATEC Spine form strategic partnership to integrate Nociscan surgical decisioning technology with AlphaInformatiX platform for spine surgery
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.28%
Tags
partnership
-
Rhea-AI Summary
Aclarion announces engagement of ten KOL surgeons to drive market traction and reimbursement. Company poised to report critical metrics for value creation. Nociscan technology shows durable clinical outcomes and potential to save healthcare system $500M annually. Aclarion selected for NIH-funded BEST Trial. CLARITY Trial to launch in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.77%
Tags
none
Rhea-AI Summary
Aclarion, Inc. was unable to file its Quarterly Report on time but has since filed it on August 25, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Aclarion, a healthcare technology company, has announced a commercial agreement with The Imaging Center in Grand Rapids, MI. The agreement will provide physicians with access to Nociscan, an AI-enabled decision support tool for identifying the source of chronic low back pain. This partnership presents a marketing opportunity for spine surgeons, pain management physicians, and chiropractors. Aclarion aims to expand patient access through commercial agreements and improve patient care while reducing costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.08%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
77.97%
Tags
none
Aclarion Inc

Nasdaq:ACON

ACON Rankings

ACON Stock Data

4.62M
582.37k
46.39%
Health Information Services
Services-medical Laboratories
Link
United States
BROOMFIELD